Gilead Sciences Inc.
Organization details
- Legal name
- Gilead Sciences Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Foster City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GILD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000882095
- EIN
- 94-3047598
- Wikidata ID
- Q663596
Board of directors
-
Anthony Welters · DirectorSince 2023
-
Daniel Patrick O'Day · Director · Chairman & CEOSince 2023
-
Harish Manwani · DirectorSince 2023
-
Jacqueline K. Barton · DirectorSince 2023
-
Javier Rodriguez · DirectorSince 2023
-
Jeffrey Bluestone · DirectorSince 2023
-
Kelly A. Kramer · DirectorSince 2023
-
Kevin E. Lofton · DirectorSince 2023
-
Sandra Horning · DirectorSince 2023
- Since 2024
Chief executives
Solid · grade C
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 50% of the scoring weight is on file.
- Dividends 15%
- 67
- Revenue growth 20%
- 58
- Earnings growth 15%
- 69
dividend grew 4.8% a year
4.2% a year in revenue
7.2% a year in earnings per share
50% of the scoring weight is on file. Figures cover December 2018 – December 2025.
Director election results
Annual meeting of April 30, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.1%
-
96.1%
-
96.3%
-
96.3%
-
97.0%
-
98.0%
-
98.3%
-
98.4%
-
98.6%
Board connections
7 of this board's directors also sit on 16 other boards. 10 are in the same sector.
- via Kelly A. Kramer
-
DaVita Inc. Same sectorvia Javier Rodriguez
- via Kelly A. Kramer
-
Jazz Pharmaceuticals plc Same sectorvia Ted W. Love
-
Lisata Therapeutics Inc. Same sectorvia Ted W. Love
- via Anthony Welters
-
Medtronic plc. Same sectorvia Kevin E. Lofton
-
MiniMed Group Inc. Same sectorvia Kevin E. Lofton
-
Moderna Inc. Same sectorvia Sandra Horning
-
Olema Pharmaceuticals Inc. Same sectorvia Sandra Horning
-
Revolution Medicines Inc. Same sectorvia Sandra Horning
-
Royalty Pharma plc Same sectorvia Ted W. Love
- via Kelly A. Kramer
-
Structure Therapeutics Inc. Same sectorvia Ted W. Love
- via Anthony Welters
- via Harish Manwani
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $112,263,220
- 86 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | Open-market sale | −3,399 | $164.11 | $557,810 |
| Nov 5, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Option exercise | +9,810 | $72.34 | $709,655 |
| Nov 5, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −9,810 | $175.17 | $1,718,418 |
| Nov 4, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Option exercise | +102,619 | $72.34 | $7,423,458 |
| Nov 4, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −102,619 | $175.16 | $17,975,021 |
| Nov 2, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −1,600 | $167.40 | $267,840 |
| Nov 2, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −1,700 | $168.10 | $285,771 |
| Nov 2, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −1,904 | $169.27 | $322,296 |
| Nov 2, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −7,796 | $170.35 | $1,328,070 |
| Nov 2, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −2,000 | $171.06 | $342,125 |
| Oct 30, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Option exercise | +15,881 | $72.34 | $1,148,832 |
| Oct 30, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −15,881 | $175.25 | $2,783,075 |
| Oct 15, 2026 | Dickinson Andrew D Officer (Chief Financial Officer) | Open-market sale | −3,000 | $156.22 | $468,660 |
| Oct 15, 2026 | Johanna Mercier Officer (Chief Comm & Corp Aff Officer) | Open-market sale | −3,000 | $156.22 | $468,660 |
| Oct 1, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Open-market sale | −12,000 | $147.72 | $1,772,628 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Gilead Sciences Inc.
Who is the CEO of Gilead Sciences Inc.?
Daniel Patrick O'Day has been Gilead Sciences Inc.'s Chairman & CEO since March 2019.
How many directors are on Gilead Sciences Inc.'s board?
Gilead Sciences Inc.'s board has 10 directors: Anthony Welters, Daniel Patrick O'Day, Harish Manwani, Jacqueline K. Barton, Javier Rodriguez, Jeffrey Bluestone, Kelly A. Kramer, Kevin E. Lofton, Sandra Horning and Ted W. Love.
Are Gilead Sciences Inc. insiders buying or selling shares?
Over the last 12 months, Gilead Sciences Inc. insiders made no open-market purchases and sold $112.3 million of shares in 86 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="gilead-sciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.